These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 24750292)
1. Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes. Murai K; Kowata S; Shimoyama T; Yashima-Abo A; Fujishima Y; Ito S; Ishida Y Eur J Haematol; 2014 Oct; 93(4):290-6. PubMed ID: 24750292 [TBL] [Abstract][Full Text] [Related]
2. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Lonial S; Waller EK; Richardson PG; Jagannath S; Orlowski RZ; Giver CR; Jaye DL; Francis D; Giusti S; Torre C; Barlogie B; Berenson JR; Singhal S; Schenkein DP; Esseltine DL; Anderson J; Xiao H; Heffner LT; Anderson KC; Blood; 2005 Dec; 106(12):3777-84. PubMed ID: 16099887 [TBL] [Abstract][Full Text] [Related]
3. Physiologic role of TPO in thrombopoiesis. Miyazaki H Stem Cells; 1996; 14 Suppl 1():133-8. PubMed ID: 11012213 [TBL] [Abstract][Full Text] [Related]
4. Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration. Waight CC; Cain R J Oncol Pharm Pract; 2014 Oct; 20(5):351-5. PubMed ID: 24154652 [TBL] [Abstract][Full Text] [Related]
5. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. Lev PR; Grodzielski M; Goette NP; Glembotsky AC; Espasandin YR; Pierdominici MS; Contrufo G; Montero VS; Ferrari L; Molinas FC; Heller PG; Marta RF Br J Haematol; 2014 Jun; 165(6):854-64. PubMed ID: 24673454 [TBL] [Abstract][Full Text] [Related]
6. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production. Abraham M; Weiss ID; Wald H; Wald O; Nagler A; Beider K; Eizenberg O; Peled A Br J Haematol; 2013 Oct; 163(2):248-59. PubMed ID: 23906028 [TBL] [Abstract][Full Text] [Related]
7. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Iraqi M; Perdomo J; Yan F; Choi PY; Chong BH Haematologica; 2015 May; 100(5):623-32. PubMed ID: 25682608 [TBL] [Abstract][Full Text] [Related]
8. The effect of decitabine on megakaryocyte maturation and platelet release. Wang J; Yi Z; Wang S; Li Z Thromb Haemost; 2011 Aug; 106(2):337-43. PubMed ID: 21713321 [TBL] [Abstract][Full Text] [Related]
9. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid. Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564 [TBL] [Abstract][Full Text] [Related]
10. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Horie K; Miyazaki H; Hagiwara T; Tahara E; Matsumoto A; Kadoya T; Ogami K; Kato T Exp Hematol; 1997 Feb; 25(2):169-76. PubMed ID: 9015217 [TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin: biology and clinical potentials. Miyazaki H; Kato T Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146 [TBL] [Abstract][Full Text] [Related]
12. Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors. Jarocha D; Vo KK; Lyde RB; Hayes V; Camire RM; Poncz M Blood Adv; 2018 Mar; 2(6):597-606. PubMed ID: 29545255 [TBL] [Abstract][Full Text] [Related]
13. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267 [TBL] [Abstract][Full Text] [Related]
14. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation. Matsuki E; Miyakawa Y; Yamane A; Okamoto S Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620 [TBL] [Abstract][Full Text] [Related]
15. miRNAs can increase the efficiency of ex vivo platelet generation. Emmrich S; Henke K; Hegermann J; Ochs M; Reinhardt D; Klusmann JH Ann Hematol; 2012 Nov; 91(11):1673-84. PubMed ID: 22763947 [TBL] [Abstract][Full Text] [Related]
16. Micro-concentration Lipopolysaccharide as a Novel Stimulator of Megakaryocytopoiesis that Synergizes with IL-6 for Platelet Production. Wu D; Xie J; Wang X; Zou B; Yu Y; Jing T; Zhang S; Zhang Q Sci Rep; 2015 Sep; 5():13748. PubMed ID: 26330186 [TBL] [Abstract][Full Text] [Related]
17. The role of platelet factor 4 in radiation-induced thrombocytopenia. Lambert MP; Xiao L; Nguyen Y; Kowalska MA; Poncz M Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1533-40. PubMed ID: 21740995 [TBL] [Abstract][Full Text] [Related]
18. Regulation of megakaryocyte colony forming cell numbers and ploidy by dideoxynucleosides in immunodeficient mice. Chow FP; Ordóñez JV; Sutton PA; Hamburger AW Am J Hematol; 1993 Dec; 44(4):249-55. PubMed ID: 8237995 [TBL] [Abstract][Full Text] [Related]
20. Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation. Huang J; Huang S; Ma Z; Lin X; Li X; Huang X; Wang J; Ye W; Li Y; He D; Yang M; Pan J; Ling Q; Li F; Mao S; Wang H; Wang Y; Jin J Thromb Haemost; 2021 Feb; 121(2):192-205. PubMed ID: 32961571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]